Here are our fantastic #DDRCT25 attendees! We’ve had a wonderful first day and can’t wait to see what’s in store for the next couple of days!🫶🧬
#FusionDNA #FusionCancerResearch

30.06.2025 10:24 — 👍 1    🔁 1    💬 0    📌 0

What an incredible few days it’s been with the amazing #Nucleic25 participants! 🌟
We can’t wait to celebrate all together at the Gala Dinner this evening! 🎉

06.07.2025 07:53 — 👍 7    🔁 3    💬 3    📌 0

We will be presenting this story at @fusionconf.bsky.social nucleic acids meeting July 4-7!

01.07.2025 16:01 — 👍 1    🔁 0    💬 0    📌 0

This was an awesome collaborative team effort by scientists from @mayoclinic.org @charlesuni.cuni.cz and @newcastleuni.bsky.social

30.05.2025 21:26 — 👍 0    🔁 0    💬 0    📌 0

Topobexin targets the Topoisomerase II ATPase domain for beta isoform-selective inhibition and anthracycline cardioprotection Nature Communications - In this work, authors develop obex inhibitors that target a distinct binding pocket in the ATPase domain of Topoisomerase II. They demonstrate how Topobexin, a Topoisomerase...

Topobexin is an inhibitor that targets Topoisomerase IIβ's ATPase domain—protecting the heart from anthracycline chemo damage without reducing anticancer power. Read our article about this potentially game-changer in cardio-oncology @natcomms.nature.com rdcu.be/en4ak.

30.05.2025 21:23 — 👍 1    🔁 0    💬 2    📌 0